Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib.

MLA

Sato, Yuki, et al. “Successful Intracranial Response of Lorlatinib after Resistance with Alectinib and Brigatinib in Patients with ALK-Positive Lung Adenocarcinoma: Implications of CNS Penetration Rate of Brigatinib.” Thoracic Cancer, vol. 15, no. 23, Aug. 2024, pp. 1772–75. EBSCOhost, https://doi.org/10.1111/1759-7714.15395.

APA

Sato, Y., Sato, Y., Irie, K., Nanjo, S., Hara, S., Fujiwara, S., & Tomii, K. (2024). Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib. Thoracic Cancer, 15(23), 1772–1775. https://doi.org/10.1111/1759-7714.15395

Chicago

Sato, Yuki, Yoshiharu Sato, Kei Irie, Shigeki Nanjo, Shigeo Hara, Satoru Fujiwara, and Keisuke Tomii. 2024. “Successful Intracranial Response of Lorlatinib after Resistance with Alectinib and Brigatinib in Patients with ALK-Positive Lung Adenocarcinoma: Implications of CNS Penetration Rate of Brigatinib.” Thoracic Cancer 15 (23): 1772–75. doi:10.1111/1759-7714.15395.